Rapport Therapeutics Announces $200 Million Stock and $150 Million Convertible Note Offerings
Rapport Therapeutics also announced a private placement. Its shares fell 19% after hours to $22.19.
By Josh BeckermanShares of Rapport Therapeutics declined as it announced offerings of $200 million of stock and $150 million of convertible notes, and a private placement.The stock was down 19% after hours to $22.19. As of the market close, it was down about 9% this year.Rapport is developing drugs…